China has approved emergency use of Sinovac's COVID-19 vaccine in young people aged between three and 17, as reported in Fidelity.
When that vaccine will be offered to younger groups depends on health authorities formulating China's inoculation strategies, Chairman Yin Weidong.
Yin said minors have lower priority for vaccination against the coronavirus compared with the elderly, who face higher risk of severe symptoms after infection.
Preliminary results from Phase I and II clinical trials showed the vaccine could trigger immune response in three to 17 year-old participants, and most adverse reactions were mild.
Meanwhile, Sinopharm, which has two shots using similar technology to Sinovac's product, is also submitting data for clearance in younger groups.
A vaccine from CanSino Biologics', adopting a different technique, has entered Phase II testing involving those aged between six and 17.